首页> 美国卫生研究院文献>other >Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib Highlights Need for Individualized Therapy
【2h】

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib Highlights Need for Individualized Therapy

机译:具有亚硒酸盐和硼替佐米的实质作用的恶性间皮瘤细胞系药物敏感性的变化凸显了个体化治疗的需求

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundMalignant mesothelioma cells have an epithelioid or sarcomatoid morphology, both of which may be present in the same tumor. The sarcomatoid phenotype is associated with worse prognosis and heterogeneity of mesothelioma cells may contribute to therapy resistance, which is often seen in mesothelioma. This study aimed to investigate differences in sensitivity between mesothelioma cell lines to anti-cancer drugs. We studied two novel drugs, selenite and bortezomib and compared their effect to four conventional drugs. We also investigated the immunoreactivity of potential predictive markers for drug sensitivity; Pgp, MRP-1, ERCC1, RRM1, TS, xCT and proteasome 20S subunit.
机译:背景恶性间皮瘤细胞具有上皮样或肉瘤样形态,两者都可能存在于同一肿瘤中。肉瘤样表型与更差的预后相关,间皮瘤细胞的异质性可能导致治疗耐药性,这在间皮瘤中很常见。这项研究旨在调查间皮瘤细胞系对抗癌药的敏感性差异。我们研究了两种新药亚硒酸盐和硼替佐米,并将它们与四种常规药物的作用进行了比较。我们还研究了潜在的预测标志物对药物敏感性的免疫反应性。 Pgp,MRP-1,ERCC1,RRM1,TS,xCT和蛋白酶体20S亚基。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号